Member Info for CHELSEA7

Which is why Botski I feel they have something very important to say. Deapite not being so happy with communication this year, there is still much to like and look forward too, especially at this price.

Haven"t felt fully confident for a while now, but yes I can see that much we would like to hear, cant be spoken about, and IMHO it is very plausible to hope for news we want to see. Should be an interesting ride.

Buys 124k

Sells 180k

Falsedawn, very aware of that, which is why that alternate funding sprung to mind. Placings have indeed gone hand in hand with Proactive in recent times, the reason why I don"t think another of that kind is going to happen in November, is simply due to our cash position now, and no need just yet with a very depressed share price to do so.

Was barely able to sleep last night, after learning we are down for the above event. It seems historically we have followed this path after news to a wider audience.

Apart from an early reaction to it, I was busy creating scenarios I would like/ and be very happy to see develop. One such thought which we have discussed a few times, that being ready for the American market, partnered by BioNTech/ Genentech listed for an IPO for primarily our platforms to secure in partnership all the funding needed to see Moditope through trials. Considering our M/Cap has slid to sub £40m just maybe it is the time for that move, with a big partner, and potentially, thinking of Grand Challenge for one, a lot of credibility to unlock our full potential, value the company, at a much higher valuation than we currently have.

Any thoughts on such a development, the more I think of it, it could indeed happen, and fit into timelines to kick off trials in 2019? I just wonder...………………..

Thanks. Yes we do a couple of Proactive Forums every year. Didn't know about this one, and how interesting is the date? Just after this years AGM.!!!! Bodes well for those of us that think there is much to discuss, which will hoprful br RNSed before the AGM. Good news indeed we have a platform to reach investors, I just wonder whether we will get funding news, explaining the silence, which leads to interviews with Proactive and press releases.

Yes, good news indeed. Goodnight, a very long day.

Very refreshing to have you on board. Enjoyed your posts, funny enough whilst waiting for the first of four biopsies at UCLH McMillen Centre, so it goes without saying where my thoughts were for your relative.

Sadly on the other hand, having to read the endless rows and personals which have blighted this share for many years, was just . a reminder of how many good posters who choose not to post here as a result. FYI I haven"t even glanced at the ADVFN BB, it goes beyond contempt, given the nature of the topic, and the scope for discussion that exists. Never thought I"d say this, but some might benefit from being around cancer sufferers, laid bare by there condition, bristling with hope, and egos laid non existent, unlike hear.

So good luck here, you are right, there is much to like here, but it has been a slog at times, one i think will have a happy ending

Still making out you have filtered me??

The truth hurts

Oh Freddie, it is all from the precious RNSs that you rampers swear by!!!!

Why do you feel a deal is even close?????

And there is VAL 201

Where is the deal??????

101 and 401 to follow. Out today, address the issues, all they say is "dose escalation" normally followed by placings.

Close to a deal??????..................................
11th January 2017 - Building on these positive results, ValiRx is adding additional clinical sites to participate in the dose-escalating, therapeutically relevant phase of the trial to arrive at the maximum tolerated dose. And Satu added – ‘We anticipate that by increasing the dosage we will show a high level of efficacy without compromising the safety and tolerability shown to date to meet the needs of those patients currently under-served by current therapies. ValiRx is entering a very exciting phase, which should result in the crystallisation of substantial value.’
So, just the six years of dose escalation so far...but then, on 28 February 2017 – ‘PEER-REVIEWED PUBLISHED ARTICLES SUPPORTING VALIRX & VALISEEK'S ANTI-CANCER TECHNOLOGY’, followed 24 hours later by (1st Mar 2017) "VALIRX RAISE £1.16M TO ACCELERATE CLINICAL TRIALS IN VAL201 & VAL401" - PLACING AND PROPOSED SUBSCRIPTION
20 September 2017 - VAL201 update – ‘The Company notes speculation as to the status of its VAL201 clinical trial and confirms that the trial is ongoing and looks forward to updating the market in due course.’ (That’s not an update is it?)

6th September 2018 Clinical Update – Dr Satu Vainikka, CEO of ValiRx, commented: "... VAL201 is increasingly showing its therapeutic potential...’

I have left out the placings – they can be counted if I get a lot more time. And nowhere in any RNS is there mention of discussions, advanced or even preliminary, or approaching deals, or interested parties, or patient numbers, or survival rates, or of much at all really. So VAL201 has been in development for 7 and a half years and all that they can say with confidence is that it hasn’t killed anyone. Now do you wonder why the share price graph looks like an Olympic ski slope?

So you want the RNSs
Posts: 33,132

Opinion:
No Opinion
Price:
1.875
Uncanny-----201 Dose escalation!!!!
8 Oct '18
So Val are in talks!!!.................

28th Jul 2011 ...in the studies thus far, VAL201 has been shown to prevent cancerous growth in live models
2nd Apr 2012
Satu quote - "The Placing ... will allow the Company to accelerate translational and developmental studies on its lead compounds, VAL201 and VAL101, and will assist the Company in the progression of these compounds from pre-clinical and into Phase I clinical trials."

24th October 2013 – ‘...this trial to commence in Q1 2014. The expanded trial is anticipated to yield early results within 8 weeks of commencement.’

1st Apr 2014 – ‘The Company is informed by the CTPT that it could proceed now, but the CTPT have recommended that a further stability and sterility study be completed...’
3rd Nov 2014 - 201 update - Dr Satu Vainikka, CEO of ValiRx, commented: "I am pleased that the trial is progressing as announced and the whole team is delivering according to the schedule in the Company's plan".
26th November 2014 ‘...the Company is expecting to have the first results relating to safety and tolerability from the first subjects during Quarter 1, 2015.’
24th Feb 2015 ‘...pleased to announce that its lead compound, VAL201 was safe and well tolerated at the doses tested.’

25th Jun 2015 The trial is now advancing through the planned dose escalation...

21st July 2015 ‘...the next dose escalation has been approved, which may prove sufficient to show anti-tumour activity.’

16th February 2016 ‘Final dose escalation approved’ (17th Feb 2016 13:00 Placing to raise £0.5 million)

17th Mar 2016 VALIRX ENGAGES US INVESTOR RELATIONS FIRM – and...?
19th May 2016 201...has shown a high degree of safety, with no drug related significant adverse events being reported.
7th June 2016 - To date, no drug related significant adverse events have been reported. Dose escalation has reached therapeutic levels and the studies have shown early indications of efficacy. (So here we are, 30 months later and nothing. Anyway, what’s an early indication of efficacy? It either shows efficacy or it doesn’t, so that then begs the question of why call something a ‘therapeutic dose’ if the best it does is offer an ‘early indication’?)
29th November 2016 – Clinical update - ....VAL201, continues to perform well in its "Phase I/II dose escalation study to assess safety and tolerability of VAL201.... The study is a titration, open label, dose-escalation trial designed to identify a maximum tolerated or administered dose (MTD/MAD).
11th January 2017 - Building on these positive results, ValiRx is adding additional clinical sites to participate in the dose-escalating, therapeutically relevant phase of the trial to arrive at the maximum tolerated dose. And Satu added – ‘We anticipate that by increasing the dosage we will show a high level of efficacy without compromising the safety and toler

""Read the RNS’s Chelsea and listen to the Podcasts - quite clear where VAL are now, where they are going and where they want to be"""

Well as you know i have done more than that, will repeat what i posted last week on 201 for now, the "dose escalation trial" In fact go back to the 8th October and there are three posts all about 201, taken from all RNSs, and i ask you again, what makes you feel a deal is near????

Time to stop misleading and read what you claim i haven"t done. Unbelievale!!!.

Hence the tick down...…………………..

Latest Trades
Date & Time
Volume
Price
15/10/2018 08:22
53,000
9.58
15/10/2018 08:20
10,000
9.72

I think it was late last week, that one trade, delayed, surprised me no end. It was over on NEX, late afternoon a sell for 75k at 9.66. I understood the selling from 14p down, but just wondered at this stage was it not, after waiting so long, worth holding at this time, so close to the AGM, for a little bit longer? or are we seeing money taken out of AIM because of the negative outlook for world wide markets, which along with poor volumes of buying I am sure goes some way to explain our recent woes.

Been trying to get myself to break my promise about buying more, I would have jumped at buying 30k around 10p, but with a happy bank balance, returning to my oncologist, and Xmas nearly upon us have reluctantly opted out of temptation.

Will we get news before the AGM? ….not so sure, will we be happy what we hear at the AGM? I believe so, and more, and then we have the Grand Challenge results, which might well bring on commercial deal news.I certainly envy those who are buying in at this level. I do believe our collaborations will bear fruit for Moditope trials, and admire our BOD for building the relationships they have, which is the basis for my confidence. Not exactly without cause to be very hopeful, we have been here before, but IMHO never so well placed.

So yes, to a much better week for all, and to the beginning of an exciting period, IMHO the next few weeks will be the catalyst for what we have waited so long for. Good luck all, whatever you choose.

a

Val Ju, you don"t bother me one bit, it was you bad mouthing me, remember. In fact, none of you rampers bother me, you cannot back up your posts, ever.

So uncanny, you reckon something is brewing, lol, why is that?

Val Ju, I have explained many times, hasn"t changed, my interest in Biotechs, particularly Cancer Drugs.

It is interesting my presence bothers you so much, I just want to bring some balance to the ramping which goes on here.

Woody even a couple of days ago, I said I was down 38% in my own Biotech choice, so you both can demonise me all you like. I stated there is nothing more I want to see than a successful treatment to be used on patients, the only reply to anything, challenging what Is posted, is insults and abuse. Never an answer, simply because you cannot prove up the misinformation that you post.

So prove what you say, you know a two way debate, you might even like it. Fortunately there are many here who can now see beyond the greed and the desperation that a falling SP brings.

And of course do"t make up nonsense about me, keep it factually, and see my posts from even last week. That is the way here, remove anybody that disagrees with yo, insult them and make up fase information as you go. After all you are experts at that. Goodnight.

Just a reminder from John Flencrosses tweet on August 14th...………………..

John Glencross
‏


@GlencrossJohn
Follow
Follow @GlencrossJohn

More
Good chat with Cliff Holloway, CEO of @scancellpharma, this morning. The SCIB1 combo trial previously announced by the company is on track with those sites already selected expected to initiate the study by year end as planned.
3:09 am - 14 Aug 2018 From Sheffield, England

Regardless of what is discussed at the AGM, it would be good to have this news RNSed before AGM. Volume last week was very low ,and I do believe confirmation of this trial will inspire a few buyers to push this back up to the 12p level. Not around so much early this week, encouraging to see some new posters posting here, we really do seem to come under a comeback share at the current level.

Look forward to logging in and see some positive posts, and wish us all luck in what might prove to be a very interesting period for us. ATVB and good luck.

Good morning. To find the Hardman Report mentioned type in Hardman Research Scancell and it will show the monthly publications. Note October 2018, now, is the only publication we are not in.

Hanoi, is this the same band?

https://www.bing.com/search?q=hanoi+rocks&form=EDGTCT&qs=AS&cvid=3a99bec3a41545458ff17117011de6ac&refig=b3a19e56937f453a91cb772aa4e51c8a&cc=GB&setlang=en-GB&PC=HCTS#

Will look on You Tube if it is. We could do with music at the £1 Party!!! Take care buddy

Hi Hanoi, ah so Portsmouth, you have suffered too, lol.

Seeing my oncologist Monday, first time in six months so a bit nervy. My COPD is getting worse, quickly, two nurses were here taking my oxygen in blood readings Thursday, 95/100 is OK, mine were after 10metres 80. Which is time for oxygen, hence why I am house bound, and sleep through most days, hence too my absence from day to day.

Think we have had some very good posts the last few days, we have no need for ramping, AVO reached 10p, IMM 20p, there are many more, hopeful of news in the next couple of months, and good luck to newcomers coming in now, good to see them here too, Take care buddy ATVB